{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:32:27Z","timestamp":1789417947314,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>SGLT2 inhibitors and DPP4 inhibitors have been suggested to affect lipid metabolism. However, there are few randomized controlled trials comparing the effects on the lipid metabolism between the two types of antidiabetic drugs. The SUCRE study (UMIN ID: 000018084) was designed to compare the effects of ipragliflozin and sitagliptin on serum lipid and apolipoprotein profiles and other clinical parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a multicenter, open-label, randomized, controlled trial. Patients with type 2 diabetes (20\u201374 years old) with HbA1c levels of 7.0-10.5% and serum triglyceride levels of 120\u2013399\u00a0mg\/dL (1.35\u20134.50 mmol\/L) on diet and\/or oral hypoglycemic agents were enrolled. Subjects were randomized to treatment with ipragliflozin (50\u00a0mg\/day, <jats:italic>n<\/jats:italic>\u2009=\u200977) or sitagliptin (50\u00a0mg\/day, <jats:italic>n<\/jats:italic>\u2009=\u200983). Laboratory measurements were performed at 0, 1, 3, and 6 months of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ipragliflozin and sitagliptin reduced fasting plasma glucose, glycoalbumin, and HbA1c almost equally. Ipragliflozin increased HDL-C and decreased apo E. Sitagliptin decreased TG, apo B48, CII, and CIII, but increased LDL-C. The between-treatment differences were significant for HDL-C (<jats:italic>P<\/jats:italic>\u2009=\u20090.02) and apo B48 (<jats:italic>P<\/jats:italic>\u2009=\u20090.006), and nearly significant for apo A1 (<jats:italic>P<\/jats:italic>\u2009=\u20090.06). In addition, ipragliflozin reduced body weight, blood pressure, serum liver enzymes, uric acid, and leptin, and increased serum ketones compared with sitagliptin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>While ipragliflozin and sitagliptin showed similar effects on glycemic parameters, the effects on serum lipid and apolipoprotein profiles were different. Ipragliflozin may have an anti-atherogenic effect through modulation of HDL-C and apo E compared to sitagliptin through TG and apo B48, CII, and CIII in patients with type 2 diabetes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-024-02149-7","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T20:02:08Z","timestamp":1707422528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study"],"prefix":"10.1186","volume":"23","author":[{"given":"Mototsugu","family":"Nagao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Tanimura-Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the SUCRE Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"issue":"19","key":"2149_CR1","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","volume":"241","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035\u20138.","journal-title":"JAMA"},{"issue":"16","key":"2149_CR2","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.114.010815","volume":"130","author":"E Selvin","year":"2014","unstructured":"Selvin E, Lazo M, Chen Y, Shen L, Rubin J, McEvoy JW, Hoogeveen RC, Sharrett AR, Ballantyne CM, Coresh J. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014;130(16):1374\u201382.","journal-title":"Circulation"},{"issue":"8","key":"2149_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/14740338.2019.1626823","volume":"18","author":"EM Lamos","year":"2019","unstructured":"Lamos EM, Hedrington M, Davis SN. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opin Drug Saf. 2019;18(8):691\u2013701.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"2149_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1517\/17425255.2015.1009893","volume":"11","author":"MS Hedrington","year":"2015","unstructured":"Hedrington MS, Davis SN. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015;11(4):613\u201323.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9548","key":"2149_CR5","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696\u2013705.","journal-title":"Lancet"},{"key":"2149_CR6","doi-asserted-by":"publisher","first-page":"i2231","DOI":"10.1136\/bmj.i2231","volume":"353","author":"F Salvo","year":"2016","unstructured":"Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, Begaud B, Pariente A. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ. 2016;353:i2231.","journal-title":"BMJ"},{"issue":"1","key":"2149_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40360-019-0293-y","volume":"20","author":"D Liu","year":"2019","unstructured":"Liu D, Jin B, Chen W, Yun P. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2019;20(1):15.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"14","key":"2149_CR8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"9982","key":"2149_CR9","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067\u201376.","journal-title":"Lancet"},{"issue":"8","key":"2149_CR10","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jdiacomp.2015.07.011","volume":"29","author":"XY Liu","year":"2015","unstructured":"Liu XY, Zhang N, Chen R, Zhao JG, Yu P. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. J Diabetes Complications. 2015;29(8):1295\u2013303.","journal-title":"J Diabetes Complications"},{"issue":"17","key":"2149_CR11","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Comparison of the effects of Glucagon-Like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for Prevention of Major adverse Cardiovascular and renal outcomes in type 2 diabetes Mellitus. Circulation. 2019;139(17):2022\u201331.","journal-title":"Circulation"},{"issue":"10166","key":"2149_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"10365","key":"2149_CR13","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"G Consortium SiM-AC-RT","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies, Consortium SiM-AC-RT G. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801.","journal-title":"Lancet"},{"issue":"12","key":"2149_CR14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","volume":"65","author":"E Marilly","year":"2022","unstructured":"Marilly E, Cottin J, Cabrera N, Cornu C, Boussageon R, Moulin P, Lega JC, Gueyffier F, Cucherat M, Grenet G. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia. 2022;65(12):2000\u201310.","journal-title":"Diabetologia"},{"issue":"9","key":"2149_CR15","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","volume":"38","author":"D Basu","year":"2018","unstructured":"Basu D, Huggins LA, Scerbo D, Obunike J, Mullick AE, Rothenberg PL, Di Prospero NA, Eckel RH, Goldberg IJ. Mechanism of increased LDL (low-Density lipoprotein) and decreased triglycerides with SGLT2 (sodium-Glucose cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol. 2018;38(9):2207\u201316.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2149_CR16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/pds.4985","volume":"29","author":"D Li","year":"2020","unstructured":"Li D, Wu T, Wang T, Wei H, Wang A, Tang H, Song Y. Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Pharmacoepidemiol Drug Saf. 2020;29(5):582\u201390.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"2149_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1463-1326.2011.01362.x","volume":"13","author":"AJ Tremblay","year":"2011","unstructured":"Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):366\u201373.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2149_CR18","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/dom.12359","volume":"16","author":"AJ Tremblay","year":"2014","unstructured":"Tremblay AJ, Lamarche B, Kelly I, Charest A, Lepine MC, Droit A, Couture P. Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes. Diabetes Obes Metab. 2014;16(12):1223\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2149_CR19","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/ijms21051835","volume":"21","author":"A Poznyak","year":"2020","unstructured":"Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes Mellitus-Atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21(5):1835.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2149_CR20","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2149_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10157-009-0224-0","volume":"14","author":"Y Kakuta","year":"2010","unstructured":"Kakuta Y, Okumi M, Ichimaru N, Abe T, Nonomura N, Okuyama A, Kojima Y, Isaka Y, Takahara S, Imai E, et al. Utility of the Japanese GFR estimation equation for evaluating potential donor kidney function. Clin Exp Nephrol. 2010;14(1):63\u20137.","journal-title":"Clin Exp Nephrol"},{"key":"2149_CR22","doi-asserted-by":"publisher","first-page":"108119","DOI":"10.1016\/j.diabres.2020.108119","volume":"162","author":"K Tanimura-Inagaki","year":"2020","unstructured":"Tanimura-Inagaki K, Nagao M, Harada T, Sugihara H, Moritani S, Sasaki J, Kono S, Oikawa S. Slim study investigators: Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes: a randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study. Diabetes Res Clin Pract. 2020;162:108119.","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"2149_CR23","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/dom.13421","volume":"20","author":"Y Tsurutani","year":"2018","unstructured":"Tsurutani Y, Nakai K, Inoue K, Azuma K, Mukai S, Maruyama S, Iizuka T, Matsuzawa Y, Saito J, Omura M, et al. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: a multicentre, randomized, prospective, open-label, active-controlled study. Diabetes Obes Metab. 2018;20(11):2675\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2149_CR24","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1111\/dom.15056","volume":"25","author":"SM Kang","year":"2023","unstructured":"Kang SM, Yun HM, Sohn M, Lim S. Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study. Diabetes Obes Metab. 2023;25(7):1922\u201331.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2149_CR25","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/dom.14288","volume":"23","author":"M Kitazawa","year":"2021","unstructured":"Kitazawa M, Katagiri T, Suzuki H, Matsunaga S, M HY, Ikarashi T, Yamamoto M, Furukawa K, Iwanaga M, Hatta M, et al. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: the N-ISM study. Diabetes Obes Metab. 2021;23(3):811\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2149_CR26","doi-asserted-by":"publisher","first-page":"586","DOI":"10.14740\/jocmr3038w","volume":"9","author":"T Kawata","year":"2017","unstructured":"Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, et al. Ipragliflozin improves Glycemic Control and decreases body Fat in patients with type 2 diabetes Mellitus. J Clin Med Res. 2017;9(7):586\u201395.","journal-title":"J Clin Med Res"},{"issue":"4","key":"2149_CR27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262\u2013275e269.","journal-title":"J Am Soc Hypertens"},{"issue":"6","key":"2149_CR28","doi-asserted-by":"publisher","first-page":"e004007","DOI":"10.1161\/JAHA.116.004007","volume":"6","author":"M Mazidi","year":"2017","unstructured":"Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose Cotransport-2 inhibitors on blood pressure in people with type 2 diabetes Mellitus: a systematic review and Meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6(6):e004007.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"2149_CR29","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783\u201394.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"2149_CR30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","volume":"32","author":"MJ Chapman","year":"2011","unstructured":"Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345\u201361.","journal-title":"Eur Heart J"},{"issue":"3","key":"2149_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1194\/jlr.M018010","volume":"53","author":"RM Krauss","year":"2012","unstructured":"Krauss RM, Wojnooski K, Orr J, Geaney JC, Pinto CA, Liu Y, Wagner JA, Luk JM, Johnson-Levonas AO, Anderson MS, et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res. 2012;53(3):540\u20137.","journal-title":"J Lipid Res"},{"issue":"1\u20132","key":"2149_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0009-8981(99)00097-2","volume":"286","author":"J Davignon","year":"1999","unstructured":"Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta. 1999;286(1\u20132):115\u201343.","journal-title":"Clin Chim Acta"},{"issue":"8","key":"2149_CR33","doi-asserted-by":"publisher","first-page":"e0220659","DOI":"10.1371\/journal.pone.0220659","volume":"14","author":"EH van den Berg","year":"2019","unstructured":"van den Berg EH, Corsetti JP, Bakker SJL, Dullaart RPF. Plasma ApoE elevations are associated with NAFLD: the PREVEND Study. PLoS ONE. 2019;14(8):e0220659.","journal-title":"PLoS ONE"},{"issue":"1\u20133","key":"2149_CR34","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1\u20133):246\u201355.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"2149_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1055\/a-1304-3430","volume":"71","author":"E Kutoh","year":"2021","unstructured":"Kutoh E, Kuto AN, Wada A, Hayashi J, Kurihara R. Sitagliptin as an initial therapy and Differential regulations of metabolic parameters depending on its glycemic response in subjects with type 2 diabetes. Drug Res (Stuttg). 2021;71(3):157\u201365.","journal-title":"Drug Res (Stuttg)"},{"issue":"3","key":"2149_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pcd.2018.02.001","volume":"12","author":"S Seidu","year":"2018","unstructured":"Seidu S, Kunutsor SK, Cos X, Gillani S, Khunti K, For, on behalf of Primary Care Diabetes E. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes. 2018;12(3):265\u201383.","journal-title":"Prim Care Diabetes"},{"issue":"1","key":"2149_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3803\/EnM.2019.34.1.80","volume":"34","author":"JH Bae","year":"2019","unstructured":"Bae JH, Kim S, Park EG, Kim SG, Hahn S, Kim NH. Effects of Dipeptidyl Peptidase-4 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and Meta-analysis. Endocrinol Metab (Seoul). 2019;34(1):80\u201392.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"2","key":"2149_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/dom.14251","volume":"23","author":"CM Khoo","year":"2021","unstructured":"Khoo CM, Deerochanawong C, Chan SP, Matawaran B, Sheu WH, Chan J, Mithal A, Luk A, Suastika K, Yoon KH, et al. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: an Asian perspective and expert recommendations. Diabetes Obes Metab. 2021;23(2):299\u2013317.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2149_CR39","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3803\/EnM.2020.912","volume":"36","author":"JH Bae","year":"2021","unstructured":"Bae JH, Park EG, Kim S, Kim SG, Hahn S, Kim NH. Comparative renal effects of Dipeptidyl Peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors on individual outcomes in patients with type 2 diabetes: a systematic review and network Meta-analysis. Endocrinol Metab (Seoul). 2021;36(2):388\u2013400.","journal-title":"Endocrinol Metab (Seoul)"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02149-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02149-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02149-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T20:02:23Z","timestamp":1707422543000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02149-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2149"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02149-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the principles of the Declaration of Helsinki and was approved by the ethics committees at Fukujuji Hospital, Japan Anti-Tuberculosis Association and, where appropriate, at each of the participating hospitals and clinics. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}